BioNTech is a German biotechnology company founded in 2008, primarily focused on the development of personalized immunotherapies for the treatment of cancer and other serious diseases. The company gained international prominence for its pioneering work in mRNA (messenger RNA) technology, particularly during the COVID-19 pandemic, when it partnered with Pfizer to develop one of the first COVID-19 vaccines authorized for emergency use. BioNTech’s approach involves using mRNA to instruct cells in the body to produce proteins that can trigger an immune response against specific diseases. In addition to COVID-19 vaccines, BioNTech is involved in developing therapies for various forms of cancer and infectious diseases, leveraging its expertise in innovative drug development and personalized medicine.
BioNTech reported a decrease in 2024 profits to €1.08 per share, down from €1.90, yet still surpassing market expectations of €0.407. Revenues fell to €1.19 billion, outperforming forecasts of €1.093…